middl
east
respiratori
syndrom
mer
coronaviru
emerg
pathogen
pandem
potenti
continu
caus
sporad
human
diseas
year
first
case
human
detect
zoonot
transmiss
consequ
risk
human
epidem
probabl
continu
futur
given
mer
coronaviru
appear
highli
endem
among
dromedari
camel
geograph
widespread
area
middl
east
africa
light
potenti
threat
global
public
health
along
coalit
epidem
prepared
innov
prioritis
research
develop
countermeasur
mer
coronaviru
develop
target
product
profil
prevent
reactiv
use
mer
coronaviru
vaccin
lancet
infecti
diseas
kayvon
modjarrad
colleagu
report
result
phase
openlabel
doserang
studi
first
dna
vaccin
candid
mer
coronaviru
enter
clinic
trial
studi
adult
age
year
one
site
usa
enrol
sequenti
use
doseescal
protocol
receiv
mg
mg
mg
intramuscular
inject
baselin
week
week
follow
immedi
colocalis
intramuscular
electropor
primari
outcom
studi
safeti
assess
vaccin
period
week
dose
vaccineassoci
seriou
advers
event
common
advers
event
injectionsit
reaction
particip
common
solicit
symptom
administrationsit
pain
common
unsolicit
advers
event
infect
seroconvers
measur
mer
coronaviru
spike
glycoprotein
subunit
elisa
detect
particip
first
second
inject
respect
week
neutralis
antibodi
detect
particip
week
week
two
week
mer
coronaviru
sspecif
respons
detect
particip
second
inject
third
vaccin
licens
mer
coronaviru
vaccin
current
avail
substanti
challeng
exist
develop
vaccin
includ
avail
anim
model
eg
transduc
mice
transgen
mice
rabbit
rhesu
macaqu
marmoset
alpaca
camel
might
mimic
human
diseas
immun
correl
protect
defin
protect
immun
respons
natur
infect
poorli
understood
although
humor
cellular
respons
probabl
necessari
viral
clearanc
theoret
risk
immun
enhanc
mer
coronaviru
infect
vaccin
possibl
lead
immunopatholog
pulmonari
eosinophil
infiltr
demonstr
efficaci
field
probabl
possibl
necessit
altern
regulatori
pathway
licensur
mer
shift
pattern
sporad
outbreak
pandem
spread
known
whether
vaccin
base
current
mer
coronaviru
isol
offer
protect
pandem
strain
result
modjarrad
colleagu
studi
illustr
challeng
promis
develop
vaccin
novel
pathogen
episod
outbreak
littl
avail
knowledg
despit
preclin
demonstr
protect
radiolog
histopatholog
pneumonia
mer
coronaviru
challeng
rhesu
macaqu
remain
difficult
interpret
relev
immunogen
paramet
assess
human
phase
trial
given
poor
understand
protect
natur
immun
respons
modjarrad
colleagu
sought
bridg
gap
posthoc
analysi
obtain
sampl
ten
individu
recov
natur
mer
coronaviru
infect
outbreak
south
korea
convalesc
serum
peripher
blood
mononuclear
cell
sampl
obtain
mean
month
sd
origin
mer
diagnosi
neutralis
antibodi
titr
follow
natur
infect
significantli
higher
vaccineinduc
respons
acut
phase
differ
vaccin
late
convalesc
sampl
similar
postvaccin
timepoint
given
differ
neutralis
antibodi
respons
comparison
postnatur
infect
versu
postvaccin
respons
import
role
develop
vaccin
sporad
occur
pathogen
mer
coronaviru
despit
mani
challeng
develop
platform
technolog
vaccin
base
hold
promis
novel
pathogen
threat
rapid
formul
manufactur
four
mer
coronaviru
vaccin
candid
start
phase
trial
base
differ
platform
technolog
complet
phase
trial
repres
increment
import
step
develop
vaccin
emerg
viral
global
threat
intern
vaccin
institut
gwanakgu
seoul
south
korea
iki
jhk
jeromekim
iviint
iki
jhk
institut
collabor
geneon
life
scienc
middl
east
respiratori
syndrom
coronaviru
vaccin
trial
south
korea
sinc
ebola
virus
caus
sporad
outbreak
epidem
throughout
central
west
africa
recent
year
size
durat
outbreak
grown
exponenti
exemplifi
case
death
west
african
epidem
ongo
outbreak
ituri
north
kivu
provinc
democrat
republ
congo
began
juli
spill
uganda
result
case
death
june
contrast
previou
outbreak
never
reach
hundr
case
gener
shortliv
like
emerg
rel
isol
locat
factor
lead
scale
durat
west
african
epidem
includ
limit
highli
mobil
societi
inadequ
public
health
infrastructur
absenc
approv
vaccin
mani
import
advanc
understand
ebola
viru
infect
recoveri
made
outbreak
contribut
refin
medic
countermeasur
includ
vaccin
therapeut
diagnost
develop
revers
genet
system
ie
techniqu
gener
infecti
